IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9464044 B1

PDFFull Text
Date of Patent:
Oct. 11, 2016

Filed:

Jun. 04, 2013

Compound having ability to inhibit 11beta-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient

Applicants:

Ahn-gook Pharmaceutical Co., Ltd., Seoul, KR;

Bamichem Co., Ltd., Incheon, KR;

Incheon University Industry Academic Cooperation Foundation, Incheon, KR;

Inventors:

Soon Kil Ahn, Seoul, KR;

Jin Auh, Seoul, KR;

Nam Song Choi, Cheonan-si, KR;

Chang Kyun Han, Seoul, KR;

Tae-Jeong Kim, Suwon-si, KR;

Kamsa Pae, Seoul, KR;

Young June Shin, Gimhae-si, KR;

Dong-Oh Han, Anyang-si, KR;

Cheol Kyu Han, Seoul, KR;

Assignees:

AHN-GOOK PHARMACEUTICAL CO., LTD., Seoul, KR;

BAMICHEM CO., LTD, Incheon, KR;

INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, Incheon, KR;

Attorney:

Lucas & Mercanti, LLP

Primary Examiner:

Yong Chu

Int. Cl.
CPC ...
C07C 311/19 (2006.01); C07C 311/21 (2006.01); C07C 275/28 (2006.01); C07C 311/08 (2006.01); C07C 311/29 (2006.01); C07C 237/24 (2006.01); C07D 213/82 (2006.01); C07D 215/08 (2006.01); C07D 217/06 (2006.01); C07D 231/18 (2006.01); C07D 333/34 (2006.01); C07C 311/14 (2006.01); C07D 239/42 (2006.01); C07D 241/42 (2006.01); C07D 417/12 (2006.01); C07D 275/06 (2006.01); C07D 277/36 (2006.01); C07D 209/08 (2006.01); C07D 277/56 (2006.01); C07D 295/215 (2006.01); C07D 213/70 (2006.01); C07D 307/64 (2006.01);
U.S. Cl.
CPC ...
C07C 311/21 (2013.01); C07C 237/24 (2013.01); C07C 275/28 (2013.01); C07C 311/08 (2013.01); C07C 311/14 (2013.01); C07C 311/19 (2013.01); C07C 311/29 (2013.01); C07D 209/08 (2013.01); C07D 213/70 (2013.01); C07D 213/82 (2013.01); C07D 215/08 (2013.01); C07D 217/06 (2013.01); C07D 231/18 (2013.01); C07D 239/42 (2013.01); C07D 241/42 (2013.01); C07D 275/06 (2013.01); C07D 277/36 (2013.01); C07D 277/56 (2013.01); C07D 295/215 (2013.01); C07D 307/64 (2013.01); C07D 333/34 (2013.01); C07D 417/12 (2013.01); C07C 2101/02 (2013.01); C07C 2101/18 (2013.01); C07C 2102/42 (2013.01); C07C 2103/74 (2013.01);
Abstract

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Find Patent Forward Citations

Loading…